Shots:

• The first patient has been dosed last week in a P-II/III COMET-ICE study with VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization
• The study will enroll ~ 1-300 patients globally who have an early symptomatic infection. The P-II/III study comprises of two parts: The Lead-In phase will assess the safety and tolerability of VIR-7831 (IV- 500mg) vs PBO over a 14-day period in non-hospitalized patients and aims to recruit 20 patients across the US
• Following this initial safety assessment- the Expansion phase will assess the safety and efficacy of VIR-7831 (IV) vs PBO in ~1-300 non-hospitalized participants globally. The company expects the results in Q1’21 and early access to the Ab treatment in H1’21

­ Ref: GSK | Image: GSK